Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 160

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE

Open access
Kudo, Masatoshi · 2019 · Liver Cancer

Abstract

Transarterial chemoembolization (TACE) is the only guideline-recommended global standard of care for intermediate-stage hepatocellular carcinoma (HCC). However, TACE is not beneficial for three subgroups of patients with the following characteristics: (1) conditions that easily become refractory to TACE, (2) conditions in which TACE causes deterioration of hepatic functional reserve to Child-Pugh class B, and (3) conditions that are unlikely to benefit from TACE. In the first subgroup, which includes HCCs beyond the up-to-seven criteria, the response to TACE is typically poor, and hepatic functional reserve is further impaired. This may hinder the switch to molecular-targeted therapy, resulting in a worse prognosis and shorter overall survival. Recent evidence indicates that initial lenvatinib therapy followed by TACE markedly improves overall survival in this TACE-unsuitable subpopulation. Thus, lenvatinib-TACE sequential therapy (LEN-TACE sequential therapy) may become the standard of care for patients who do not benefit from TACE. Published online: September 18, 2019

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000502905

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 160

Metadata

Authors
Kudo, M.
Venue
Liver Cancer
Publisher
S. Karger AG
Published
2019
Volume
8
Issue
5
Pages
299-311
ISSN
  • 1664-5553 (ISSN-L)
  • 2235-1795
OpenAlex
W2974589869
Cited by
160
References
5
FWCI
10.71
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.